Apart from our CEO Jackie Fairley, can anyone give me another single example of a comparable biotech on the ASX, whereby the CEO has such arrogance and contempt for shareholders that he/she would dare to concurrently sit as a director on another ASX listed company?
This is a very important matter for anyone considering investing in perennial under-performer Starpharma. I personally continue to believe it outrageous that our own CEO is not laser focused and 100% committed to our company. I refuse to leave this alone.
This company deserves better. The shareholders deserve better. Look no further than the short, medium and long-term chart for unquestionable evidence that we need a new full-time and committed CEO.
SPL’s part-time CEO
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
-0.005(4.35%) |
Mkt cap ! $45.32M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $10.36K | 93.95K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 233832 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 135616 | 8 |
View Market Depth
| Last trade - 14.03pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
11.0¢ |
Change
-0.005 ( 4.35 %) |
||||
| Open | High | Low | Volume | ||
| 11.3¢ | 11.3¢ | 11.0¢ | 41259 | ||
| Last updated 13.28pm 31/05/2024 ? | |||||
| SPL (ASX) Chart |